Tag: USFDA
Han Kun advises 3SBio in landmark Pfizer licensing deal
3SBio inks major licensing deal with Pfizer for cancer drug SSGJ-707
3SBio inks major licensing deal with Pfizer for cancer drug SSGJ-707
A 1,200-article code, five interlocking books, and one tighter leash on Chinese business. The clock to August 2026 is ticking